Tranexamic acid in the prevention of periventricular haemorrhage.
Increased fibrinolytic activity in the ganglionic eminence of the preterm human brain has been proposed as a factor in the aetiology of periventricular haemorrhage. The effect of tranexamic acid in preventing periventricular haemorrhage was evaluated in 100 infants in a double blind, randomised controlled trial. Haemorrhages developed in 22 infants who received tranexamic acid and in 20 of those who received placebo. A significant reduction in fibrin degradation products in treated infants was seen. Our study suggests that excessive fibrinolytic activity is not an important factor in the aetiology of periventricular haemorrhage and that treatment with tranexamic acid will not prevent its occurrence.
D002543:Cerebral Hemorrhage / Q000097:blood / Q000517:prevention & control*; D002552:Cerebral Ventricles; D002986:Clinical Trials as Topic; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use*; D004311:Double-Blind Method; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D006801:Humans; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000517:prevention & control*; D011897:Random Allocation; D014148:Tranexamic Acid / Q000627:therapeutic use*
D003509:Cyclohexanecarboxylic Acids; D005338:Fibrin Fibrinogen Degradation Products; D014148:Tranexamic Acid